Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma | MicrobiomeTrials← Back to trialsNCT07840001
Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-12Est. Completion: 2029-04
Enrollment target: 30 participants Locations- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Other microbiome trials you might be interested in
Gastroesophageal Cancer (GC)Hepatocellular Carcinoma (HCC)Endometrial CancerRenal Cell Carcinoma (RCC)
This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally adva…
Phoenix, United StatesEst. completion Apr 1, 2028
Clear Cell Renal Cell CarcinomaLocally Advanced Clear Cell Renal Cell CarcinomaLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
Metastatic Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v8
Stage IV Renal Cell Cancer AJCC v8
This phase II trial studies how well adavosertib works in treating patients with SETD2-deficient solid tumors that have …
Orange, United StatesEst. completion Mar 1, 2026